【摘要】 猪心移植是解决心脏移植供体少的有效方法 .由于猪心血管内皮细胞表面抗原半乳糖 α 1,3 半乳糖 (Gal α 1,3 Gal) ,能与人体内预存的天然抗体结合产生超急性排斥反应 (HAR) ,而无法应用于临床 .为了解决这一难题 ,应用噬菌体展示技术 ,筛选出一个能与抗B型血单克隆抗体 (mABanti B)特异性结合的阳性噬菌体克隆 ,应用酶联免疫吸附测定 (ELISA)和竞争性ELISA结果表明 ,所获得的阳性噬菌体克隆能特异性地与mABanti B结合 ,并且这种结合可被蜜二糖 (具有Gal α 1,6 Glc的结构 )所竞争抑制 .由此推测 ,筛选到的噬菌体阳性克隆很可能就结合在蜜二糖与mABanti B结合的位点 .同时 ,进行了阳性噬菌体克隆的抑制猪红细胞凝集活性试验 ,试验结果表明 ,此阳性克隆不仅可抑制Gal α 1,3 Gal与抗体的结合 ,也可抑制Gal α 1,3 Gal与西非单叶豆凝集素 (GS I B4)的结合 .此噬菌体阳性克隆测序后 ,得小肽序列为CCWLLRQPVRFVRSIRS .鉴于以上的结果 ,认为此小肽可以作为Gal α 1,3 Gal的模拟肽 ,同时有望开发成抗猪器官异种移植超急性排斥反应的新药更多还原

【Abstract】 The obstacle for pig-to-human transplantation is hyperacute rejection (HAR) triggered by the interaction between human natural antibodies and the antigenic epitope Gal-α-1,3-Gal. The α-Gal structure is considered to be the major xenoantigenic epitopes present on porcine tissues. A phage-displayed peptide library is used to identify a 17-amino-acid peptide CCWLLRQPVRFVRSIRS that binds to the mAb anti-B (anti-B monoclonal antibody which binds the carbohydrate Gal α-1,3 Gal).The melibiose competes with the binding of mAB anti-B to the peptide, suggesting that they may bind the same site. Using a pig RBC agglutination assay, it is shown that this peptide can inhibit the agglutination of pig RBCs by human serum or GS-I-B4.更多还原